Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Hydrochlorothiazide 12.5mg; Drug: Telmisartan 40mg; Drug: Telmisartan 80mg

Study type: Observational

Funder types: Industry

Identifiers

NCT01050062

502.542

Details and patient eligibility

About

The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.

Enrollment: 1,452 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Hypertensive patients who have never taken Micombi Tablets.

Exclusion criteria

None

Trial design

1,452 participants in 2 patient groups

Micombi® Combination Tablet AP

Treatment:

Drug: Telmisartan 40mg

Drug: Hydrochlorothiazide 12.5mg

Micombi® Combination Tablet BP

Treatment:

Drug: Telmisartan 80mg

Drug: Hydrochlorothiazide 12.5mg